# Aptevo to Participate in March 2026 Conferences
Canonical URL: https://biopharmsignal.com/news/APVO/aptevo-to-participate-in-march-2026-conferences
Ticker: APVO
Company: Aptevo Therapeutics
Source: Aptevo Therapeutics
Published: 2026-03-19 12:05 EST
Original Source URL: https://aptevotherapeutics.gcs-web.com
## Summary

SEATTLE, WA / ACCESS Newswire / March 19, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced its participation in the following

## Article Body
SEATTLE, WA / ACCESS Newswire / March 19, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced its participation in the following
## Recent Company News
- 2026-05-28 12:05 EST — [Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-appoints-mary-j-janatpour-ph-d-as-senior-vice-president-and-chief-scientific-officer) — Source: Aptevo Therapeutics
- 2026-05-27 12:05 EST — [Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing](https://biopharmsignal.com/news/APVO/aptevo-and-niowave-launch-strategic-collaboration-for-radiopharmaceutical-therapeutic-development-includes-strategic-equity-investment-by-niowave-at-closing) — Source: Aptevo Therapeutics
- 2026-05-13 12:05 EST — [Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-provides-a-1q26-business-update-rainier-on-track-for-2026-completion-and-phase-2-dose-selection) — Source: Aptevo Therapeutics
- 2026-05-06 12:05 EST — [Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection](https://biopharmsignal.com/news/APVO/aptevo-reports-87-clinical-benefit-and-81-remission-in-31-evaluable-frontline-aml-patients-through-cohort-5-substantially-outperforming-benchmark-rainier-on-track-for-2026-completion-and-phase-2-dose-selection) — Source: Aptevo Therapeutics
- 2026-03-26 12:05 EST — [Aptevo Provides State of the Business Report and 2025 Financial Results](https://biopharmsignal.com/news/APVO/aptevo-provides-state-of-the-business-report-and-2025-financial-results) — Source: Aptevo Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)